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Objective. The association between cancer and venous thrombosis is well established, however, that between malignancy
and arterial thrombosis is less well described. Isolated cases have been reported and chemotherapy has been implicated as
a cause though its significance compared with the malignant disease process itself is not known. This study examines the
outcome of patients with malignant disease who present with arterial thrombosis.
Method. Details of patients with malignant disease who presented with arterial thrombosis were analysed.
Results. Twenty patients presented with malignancy and arterial thrombosis, 16 presented in the last four years. The most
common malignancy was metastatic breast cancer. Thrombosis involved the leg in 19 cases and the arm in one. Four pa-
tients also had venous thromboembolic events and one had a carotid artery thrombosis. Eight patients underwent operative
treatment for their thrombosis. Five out of six thromboembolectomies and two out of three bypass procedures failed. Twelve
had conservative or palliative treatment. Outcome was generally poor, two patients had major amputations and seventeen
died at median follow-up of eight weeks. Survival rate from the time of presentation of arterial thrombosis was 50% at three
months and 17% at one year.
Conclusion. Patients with critical limb ischaemia due to atherosclerotic disease have an expected survival of approximately
80% at one year. The outcome of patients with arterial thrombosis associated with malignant disease is far worse. Arterial
thrombosis is an agonal event in many of these patients. Conservative or palliative treatment may be the most appropriate
management.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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Venous thromboembolism is found at post-mortem in
at least 50% of cancer patients.1 There is an overall
7-fold increased risk of venous thrombosis in patients
with malignancy compared with people without ma-
lignancy.2 A recent study analysing the risk of possi-
ble underlying malignancy in patients with venous
thromboembolism detected malignancy in 10 out of
126 (7.9%) patients with idiopathic deep venous
thrombosis (DVT).3 Arterial thrombosis in these
patients has not been widely described.
There are fewer than 50 cases of spontaneous arte-
rial thrombosis with no iatrogenic or atherosclerotic
cause in cancer patients reported in the literature.
There are isolated case reports and two studies. The
first study looked at a series of 311 patients with pan-
creatic adenocarcinoma, two (0.006%) of whom
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consecutive patients presenting over 18 months with
critical limb ischaemia (CLI) were analysed and inves-
tigated for markers of occult malignancy.5 Of these 22
(11.5%) were confirmed to have an underlying cancer.
Ten presented with acute ischaemia and 12 had
chronic ischaemia. The difference between the groups
was not significant.
Pathogenesis of thrombosis is complex and multi-
factorial in patients with malignant disease. Thrombo-
sis may be iatrogenic, related to vessel catheterisation,
surgical interventions or adjuvant treatments. It may
be related to the underlying neoplastic process. Adju-
vant therapy and the paraneoplastic process lead to
a hypercoagulable state with changes in levels of
Factor VII and proteins C and S. Tissue factor and
cancer procoagulant levels may rise. Thrombocytosis,
increased fibrinogen levels and reduced fibrinolysis,
endothelial damage and stasis may also precipitate
thrombosis.2,6e8
Major vascular reconstruction may not be appro-
priate if both the patient’s prognosis and the outcome
of surgery are poor. Prognosis of patients withn behalf of European Society for Vascular Surgery.
85Arterial Thrombosis Associated with Malignant Diseasemalignant disease who present with arterial thrombo-
sis is poorly documented. The aim of this study was to
examine the outcome of these patients.
Method
A prospective study of patients presenting with arte-
rial thrombosis who had an underlying malignancy
was carried out. All such patients were included
who presented to a vascular unit at a District General
Hospital. Patient demographics, medical history, pre-
sentation and outcomes were recorded. Kaplan-Meier
plots were used to analyse the amputation rate and
patient survival.
Results
Demographics
Twenty patients, thirteen women and seven men pre-
sented. Sixteen patients presented in the last four
years. Median age was 63 years with a range of 35 to
86. Nineteen presented with acute thrombosis. Twenty
two limbs were involved. The majority of patients (19)
presented with thrombosis involving the leg; one in-
volved the arm. Two patients had evidence of throm-
boses in both legs. Three patients had a past history
of leg ischaemia, two with intermittent claudication
secondary to peripheral vascular disease (PVD). One
underwent angioplasty 18 months previously. One
patient presented with acute limb ischaemia 6 years
previously requiring embolectomy. Of those without
a history of PVD six were smokers and one had had
a cerebrovascular accident six years previously.
Malignancy
The types of cancers, their adjuvant treatment and
outcome are shown in Table 1. Five patients alsohad a history of a primary cancer of a different origin
than their present malignant disease. Twelve patients
had metastatic disease. Sixteen had been treated with
some form of adjuvant therapy, nine within a month
prior to their presentation with arterial thrombosis.
Three had had both chemotherapy and radiotherapy.
Four patients presented with venous thromboem-
bolism either shortly before or after the arterial event.
Three of these had recurrent venous thromboses. One
patient with a leg DVT was later found to have inter-
nal jugular vein and superior vena cava thromboses.
The other two had bilateral leg DVTs, one of whom
also had a splenic infarct and pulmonary embolus.
One patient had pulmonary emboli two months after
his presentation with arterial thrombosis.
Treatment
A decision was made to manage four of the patients
with palliation only as they were moribund and their
condition deteriorated rapidly. Four others were
treated conservatively with anticoagulation, glyceryl
trinitrate patches and analgesia. Chemical sympathec-
tomy was performed in two cases. The remaining 12
had angiography. Four of these were treated conserva-
tively and eight surgically; all were given anticoagula-
tion. Five had thromboembolectomies, one bilaterally.
In three thrombectomy was not possible and they had
bypass procedures.
Outcome
Five of the six thromboembolectomies failed, four
within 24 hours and one at three weeks. The
remaining patient had some initial improvement but
then deteriorated and died six weeks later. Three
thromboembolectomies were repeated, two of these
failed. One went on to have a below-knee amputation
and died five months later. Limb survival is shown inTable 1. Type of cancers in patients presenting with arterial thrombosis and number of patients who received adjuvant therapy prior to
their arterial presentation and outcome
Lung Adenocarcinoma
unknown
primary
Colorectal Breast Leukaemia Transitional
cell
carcinoma
Ovarian Squamous
cell
carcinoma
Melanoma Non
Hodgkin’s
lymphoma
Died
Chemo 1 1 2 1 1
RT 1 2 1 1 1
Both 1
Neither 2 1 1
Alive
Chemo 1
RT
Both 2
NeitherEur J Vasc Endovasc Surg Vol 35, January 2008
86 M. Javid et al.Fig. 1. The other was treated with streptokinase which
failed and she died three weeks later.
Of the three bypass procedures two failed within
six weeks. The first, who underwent an ileofemoral
and femoropopliteal bypass had further thromboses
and died six weeks postoperatively. The second,
a femoro-femoral crossover graft, had a graft throm-
bosis two weeks post operatively and required an
above-knee amputation but died a week later. The
third who underwent a femoropopliteal bypass died
six months postoperatively.
During follow-up period seventeen patients died.
Median survival was 2.5 months [Table 1 and
Fig. 2]. Ten patients (seven men) who died had meta-
static disease. The age range of those who died was
43e86 years with a median of 67. Of those who died
13 had received adjuvant therapy, six less than
a month prior to their arterial event and nine in the
previous three months. There was a 50% survival at
three months and 17% at 12 months [Fig. 2].
Of the three survivors one had adenocarcinoma of
unknown primary origin and two had breast cancer.
Two had metastatic disease. The median age in this
group was 51 with a range of 35e72 years. Of these
one had chemotherapy within a month of their arte-
rial thrombosis and two had both chemotherapy and
radiotherapy. Only one of the survivors had been
treated surgically. One patient went on to have
a non-fatal carotid artery thrombosis 16 months after
presentation with limb thrombosis.
Discussion
This study demonstrates the poor outcome of patients
presenting with arterial thrombosis when an underly-
ing malignancy is present. Two patients (10%) under-
went major amputations, both within a month. By
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Fig. 1. Kaplan-Meier plot of limb survival during follow-up.Eur J Vasc Endovasc Surg Vol 35, January 2008contrast, the amputation rate at one year of patients
with critical limb ischaemia due to atherosclerosis is
12%.9 The survival rates of our patients are low com-
pared with patients presenting with critical limb is-
chaemia due to atherosclerotic disease. Eighty three
percent of our patients died within one year com-
pared with 80% survival at a year in PVD patients
with CLI.10 Over 95% of claudicants are alive at one
year.10 Our results are comparable to those in the
two studies previously mentioned. Schattner con-
cluded that arterial thrombosis is a terminal event in
patients with pancreatic cancer.4 In El-Sakka’s study
half of the patients died within six months.5
These patients with widespread malignancy have
a poor prognosis. The additional insult of arterial
thrombosis appears to be an agonal event in most
cases. In managing these cases consideration needs
to be given to the likely outcome. This study is the
only case series defining the outcome of such patients.
Postoperative outcome is poor. Seven out of nine
thromboembolectomies failed as did two of three
bypass procedures. The patient with the successful
bypass died six months postoperatively. Only one of
the eight patients who underwent an operation sur-
vived. El-Sakka et al.5 suggested thromboembolectomy
or angioplasty offers palliative treatment. Angioplasty
was not appropriate in any of our cases and we have
shown that attempts at revascularisation are unlikely
to be successful. Repeated attempts may be required
and are likely to fail. Although not used in our study
thrombolysis is an alternative non-invasive treatment
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Fig. 2. Kaplan-Meier plot of patient survival during follow-
up. The survival curves for patients with critical limb ische-
mia due to atherosclerotic disease (blue) and those with
intermittent claudication are also shown (taken from TASC
II study, Eur J Vasc Endovasc Surg 2007).
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radic reports in the literature. The combination of
streptokinase and urokinase transcatheter infusions
has been shown to be more effective than either
alone.11 Though patient numbers are low our results
suggest a conservative approach may be the most
acceptable. The severity of ischaemia caused by the
thrombosis may dictate whether anticoagulation or
palliative support only is more appropriate. Campbell
discusses the dilemmas involved when making these
difficult decisions and advises palliative care in ad-
vanced cases when acute limb ischaemia is just one
part of a terminal illness.12 Of our patients two of the
eight treated conservatively survived. The six who
died had an average survival of 33 weeks.
The type of cancers involved was varied and no
conclusion can be made as to the types most likely to
present with arterial thrombosis. Malignancies associ-
ated with the highest risk of venous thromboembolic
disease are haematological, lung and gastrointestinal.2
The debate as to whether extensive screening for ma-
lignancy is necessary in patients with idiopathic DVT
continues. A moderate screening strategy is recom-
mended by Oktar et al.3 which includes simple labora-
tory tests, chest radiography and abdominopelvic
ultrasonography. It is not so clear whether screening
patients with idiopathic arterial thrombosis is neces-
sary. The most common cancer in El-Sakka’s study
was lung cancer and they have recommended routine
chest radiography in all patients with CLI.5 However,
the range of cancers in our series was so varied that
any single investigation cannot be recommended as
a screening. Most of our patients did not have a history
of PVD andmany had no risk factors for thrombosis. It
could be argued that occult malignancy should be sus-
pected in those in which arterial thrombosis presents
in the absence of precipitating factors. Rigdon13 and
Mark et al.14 recommend investigation for occult ma-
lignancy where no biochemical evidence of a hyperco-
agulable state or history of PVD exists. The most
common cancer in our study was breast cancer. This
may be related to the common use of adjuvant therapy
in these patients. One study showed that premeno-
pausal breast cancer patients are more likely to present
with arterial thrombosis if they have received both
chemotherapy and tamoxifen compared with chemo-
therapy than alone.15
The significance of adjuvant therapy in the patho-
genesis and outcome of our patients is unclear. All
three of the survivors and only six of those who
died had had adjuvant therapy in the month prior
to their arterial presentation.
Five of our patients suffered other thromboembolic
events other than their primary presentation withperipheral arterial thrombosis. One developed carotid
artery thrombosis and four had venous thromboem-
bolic events. There are reports in the literature of can-
cer patients developing both arterial and venous
thromboses.13,16 It is surprising that the recording in-
cidence is not higher. It may be that many venous
thromboses remain undiagnosed.
Conclusion
Acute arterial thrombosis in the presence of active
malignancy carries a very bleak prognosis. The out-
comes from surgery are poor. Careful consideration
of palliative care may be appropriate as arterial
thrombosis is an agonal event in many.
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